Log in
Show password
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 


SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

SHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of Acceleron Pharma Inc. - XLRN

10/13/2021 | 05:57pm EDT

NEW YORK, Oct. 13, 2021 /PRNewswire/ -- Juan Monteverde, founder and managing partner at Monteverde & Associates PC, a national securities firm rated Top 50 in the 2018-2020 ISS Securities Class Action Services Report and headquartered at the Empire State Building in New York City, is investigating Acceleron Pharma Inc. (XLRN) relating to its proposed acquisition by Merck & Co., Inc. Under the terms of the agreement, XLRN shareholders are expected to receive $180.00 in cash per share they own.

The investigation focuses on whether Acceleron Pharma Inc. and its Board of Directors violated securities laws and/or breached their fiduciary duties to the Company by 1) failing to conduct a fair process, and 2) whether the transaction is properly valued.

Click here for more information: https://www.monteverdelaw.com/case/acceleron-pharma-inc. It is free and there is no cost or obligation to you.

Monteverde & Associates PC Logo

About Monteverde & Associates PC

We are a national class action securities litigation law firm that has recovered millions of dollars and is committed to protecting shareholders from corporate wrongdoing. We were listed in the Top 50 in the 2018-2020 ISS Securities Class Action Services Report. Our lawyers have significant experience litigating Mergers & Acquisitions and Securities Class Actions. Mr. Monteverde is recognized by Super Lawyers as a Rising Star in Securities Litigation in 2013, 2017-2019, an award given to less than 2.5% of attorneys in a particular field. He has also been selected by Martindale-Hubbell as a 2017-2020 Top Rated Lawyer. Our firm's recent successes include changing the law in a significant victory that lowered the standard of liability under Section 14(e) of the Exchange Act in the Ninth Circuit. Thereafter, our firm successfully preserved this victory by obtaining dismissal of a writ of certiorari as improvidently granted at the United States Supreme Court. Emulex Corp. v. Varjabedian, 139 S. Ct. 1407 (2019). Also, over the years the firm has recovered or secured over a dozen cash common funds for shareholders in mergers & acquisitions class action cases.

If you owned common stock in the Company and wish to obtain additional information and protect your investments free of charge, please visit our website or contact Juan E. Monteverde, Esq. either via e-mail at jmonteverde@monteverdelaw.com or by telephone at (212) 971-1341.

Juan E. Monteverde, Esq.
The Empire State Building
350 Fifth Ave. Suite 4405
New York, NY 10118
United States of America
Tel: (212) 971-1341

Attorney Advertising. (C) 2021 Monteverde & Associates PC. The law firm responsible for this advertisement is Monteverde & Associates PC (www.monteverdelaw.com). Prior results do not guarantee a similar outcome with respect to any future matter.

View original content to download multimedia:https://www.prnewswire.com/news-releases/shareholder-alert-monteverde--associates-pc-announces-an-investigation-of-acceleron-pharma-inc--xlrn-301399734.html

SOURCE Monteverde & Associates PC

© PRNewswire 2021
01:54aMERCK : Bristol-Myers To Shed Acceleron Stake Ahead Of Merck & Co.'s $11.5 Billion Acquisi..
10/18ACCELERON PHARMA ALERT : Investors Should Contact Bragar Eagel & Squire, P.C. Over Tender ..
10/14MERCK : Acceleron Pharma Shareholder Says Merck & Co.'s Offer Significantly Undervalues Co..
10/13SHAREHOLDER ALERT : Monteverde & Associates PC Announces an Investigation of Acceleron Pha..
10/13ACCELERON PHARMA : Holocene Advisors says Merck's offer undervalues Acceleron
10/13ACCELERON PHARMA : Holocene Advisors says Merck's offer undervalues Acceleron
10/12MERCK : Launches Tender Offer to Buy Acceleron Pharma at $180 Per Share
10/07ACCELERON PHARMA : Jefferies Starts Acceleron Pharma at Hold With $180 Price Target
10/04ACCELERON PHARMA : Raymond James Downgrades Acceleron Pharma to Market Perform From Strong..
10/01ACCELERON INVESTOR ALERT BY THE FORM : Kahn Swick & Foti, LLC Investigates Adequacy of Pri..
More news
Analyst Recommendations on ACCELERON PHARMA INC.
More recommendations